NCT05345002 2026-02-20
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
Clinical Trials
15 trialsNCT04919369 2026-02-13
All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT06358677 2026-02-13
FACE
University of Utah
Phase 2 Recruiting
NCT07348107 2026-01-16
ATARI-PDAC
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 1 Not yet recruiting
NCT04241276 2026-01-07
STARPAC2
Queen Mary University of London
Phase 2 Active not recruiting
NCT07296445 2025-12-29
LATITUDE
SDK Therapeutics, Inc.
Phase 3 Not yet recruiting
NCT04113863 2025-12-18
ATRA
Mario Negri Institute for Pharmacological Research
Phase 2 Terminated
NCT01409161 2025-12-17
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06439888 2025-12-01
LySATRA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT06731140 2025-11-17
Resilire
Fudan University
Phase 2 Recruiting
NCT06528769 2025-09-30
Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT07187505 2025-09-23
Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia
Anhui Medical University
Phase NA Active not recruiting
NCT04305041 2025-08-29
KEYMAKER-U02
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT05999812 2025-05-25
Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer
University of Texas Southwestern Medical Center
Phase 2 Active not recruiting
NCT06536413 2025-04-08
ATRA
The Methodist Hospital Research Institute
Phase 1/2 Recruiting